Long-Term Retention of Gadolinium in Bone

Main Inclusion Criteria:

• Patient scheduled for an orthopaedic surgical procedure
• A minimum of 1 month has elapsed between GBCA dose and scheduled orthopaedic surgical procedure
• Patient belongs to one of the following subgroups with respect to the number of GBCA doses received and the status of their renal function:
• patient has stable impaired renal function (at least moderate impairment, eGFR ≤ 60 ml/min/1.73 m2) and has received one GBCA injection at the standard dose (0.025 mmol per kg body weight for Gadoxetic acid and 0.1 mmol per kg body weight for all other agents) or
• patient has stable impaired renal function (at least moderate impairment, eGFR ≤ 60 ml/min/1.73 m2) and has received more than one injection of the same GBCA or
• patient has stable normal renal function (eGFR > 60 ml/min /1.73 m2) and has received one GBCA injection at the standard dose (0.025 mmol per kg body weight for Gadoxetic acid and 0.1 mmol per kg body weight for all other agents) or
• patient has stable normal renal function (eGFR > 60 ml/min/1.73 m2) who have received more than one injection of the same GBCA

Main Exclusion Criteria:

• Patient has received different GBCAs.
• Patient has received intra-articular GBCA or per any other non-i.v. route
• Patient has received any investigational product or has participated in any other clinical trial within 30 days prior to enrolling in this study.